ATE495192T1 - Mit voluminösen oder lipophilen gruppen modifizierte cyctotoxische peptide - Google Patents

Mit voluminösen oder lipophilen gruppen modifizierte cyctotoxische peptide

Info

Publication number
ATE495192T1
ATE495192T1 AT99941773T AT99941773T ATE495192T1 AT E495192 T1 ATE495192 T1 AT E495192T1 AT 99941773 T AT99941773 T AT 99941773T AT 99941773 T AT99941773 T AT 99941773T AT E495192 T1 ATE495192 T1 AT E495192T1
Authority
AT
Austria
Prior art keywords
cyctotoxic
voluminous
lipophilic groups
peptides modified
well
Prior art date
Application number
AT99941773T
Other languages
English (en)
Inventor
John Svendsen
Yystein Rekdal
Baldur Sveinbjyrnsson
Lars Vorland
Original Assignee
Lytix Biopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As
Application granted granted Critical
Publication of ATE495192T1 publication Critical patent/ATE495192T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT99941773T 1998-08-28 1999-08-31 Mit voluminösen oder lipophilen gruppen modifizierte cyctotoxische peptide ATE495192T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9818938.4A GB9818938D0 (en) 1998-08-28 1998-08-28 Bioactive peptides
PCT/GB1999/002850 WO2000012541A2 (en) 1998-08-28 1999-08-31 Cytotoxic peptides modified by bulky or lipophilic moieties

Publications (1)

Publication Number Publication Date
ATE495192T1 true ATE495192T1 (de) 2011-01-15

Family

ID=10838089

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99941774T ATE513847T1 (de) 1998-08-28 1999-08-31 Bioaktive peptide
AT99941773T ATE495192T1 (de) 1998-08-28 1999-08-31 Mit voluminösen oder lipophilen gruppen modifizierte cyctotoxische peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99941774T ATE513847T1 (de) 1998-08-28 1999-08-31 Bioaktive peptide

Country Status (12)

Country Link
US (3) US7439228B2 (de)
EP (2) EP1109827B1 (de)
JP (1) JP5475937B2 (de)
AT (2) ATE513847T1 (de)
AU (2) AU772176B2 (de)
CA (2) CA2340326A1 (de)
DE (1) DE69943130D1 (de)
DK (1) DK1109831T3 (de)
ES (1) ES2359616T3 (de)
GB (1) GB9818938D0 (de)
NO (1) NO333073B1 (de)
WO (2) WO2000012541A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283315B2 (en) 1998-08-28 2012-10-09 Lytix Biopharma As Inhibition of tumour growth
GB0605685D0 (en) * 2006-03-21 2006-05-03 Lytix Biopharma As Inhibition of tumour growth
GB9818938D0 (en) 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
GB0005702D0 (en) * 2000-03-09 2000-05-03 Alpharma As Method
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
KR20020080731A (ko) * 2001-04-17 2002-10-26 주식회사 이지바이오 시스템 락토페리신 유전자 및 이를 도입한 락토페리신 발현용형질전환체
KR100454595B1 (ko) 2001-11-30 2004-10-28 주식회사 이지바이오 시스템 락토페리신 유전자 및 이를 도입한 형질전환 대장균
SE0200598D0 (sv) * 2002-02-27 2002-02-27 A & Science Invest Ab Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
EP2286827A1 (de) 2002-05-10 2011-02-23 Agennix Incorporated Lactoferrin in der Behandlung maligner Neoplasmen und anderer hyperproliferativer Erkrankungen
WO2004003195A1 (en) * 2002-06-28 2004-01-08 The Government Of The United States Of America,As Represented By The Secretary Of The Department Of Health And Human Services Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins
NO20031818D0 (no) * 2003-04-23 2003-04-23 Uni I Tromsoe Fremgangsmåte av bioaktiv peptid forberedelse
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
CN1838965B (zh) 2004-03-19 2011-07-06 森永乳业株式会社 用于癌症治疗的药品
KR20070056042A (ko) * 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
US8034762B2 (en) * 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
CA2587727A1 (en) * 2004-11-19 2006-05-26 Jagat Rakesh Kanwar Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
DE102005051366A1 (de) * 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
WO2007055578A1 (en) * 2005-11-11 2007-05-18 Leids Universitair Medisch Centrum Cyclic antimicrobial peptides derived from lactoferrin
DE602006020617D1 (de) * 2005-12-30 2011-04-21 Evonik Roehm Gmbh Lactoferrin-peptide, geeignet als in die zelle eindringende peptide
ES2321358B1 (es) * 2006-04-05 2010-03-05 Consejo Susperior De Investigaciones Cientificas Uso de peptidos derivados de la lactoferrina para preparar formulaciones inhibidoras de la enzima conversora de angiotensina i.
JP2009535027A (ja) * 2006-04-27 2009-10-01 シンガポール ヘルス サービシーズ ピーティーイー リミテッド 抗菌ペプチド
EP2078529B1 (de) 2006-07-10 2014-12-10 PBA3 Biomed GmbH Antimikrobielle Peptide
GB0821616D0 (en) * 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
EP2754450A1 (de) * 2013-01-11 2014-07-16 Österreichische Akademie der Wissenschaften Aus Lactoferricin abgeleitete Peptide
GB201401877D0 (en) * 2014-02-04 2014-03-19 Univ Tromsoe Peptides
US20170296629A1 (en) * 2014-10-08 2017-10-19 Keio University Inhibitor of extracellular trap formation in leukocyte
ITUB20153058A1 (it) * 2015-08-11 2017-02-11 Farmagens Health Care S R L Roma ?frammento di lattoferrina per uso come agente antibatterico ed antivirale?
WO2017223098A1 (en) * 2016-06-21 2017-12-28 The Curators Of The University Of Missouri Bis-amino acid based compound and use thereof
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
WO2019028463A1 (en) * 2017-08-04 2019-02-07 Bioventures, Llc LINEAR LIPOPEPTIDE PAENIPEPTINS AND METHODS OF USE
US11236138B2 (en) * 2020-01-14 2022-02-01 Renorigin Innovation Institute Co., Ltd. Peptide, method and composition for melanin polymerization and hair darkening
CN115073352A (zh) * 2022-06-28 2022-09-20 吉尔多肽生物制药(大连市)有限公司 一种2,5,7-三叔丁基色氨酸的合成方法
CN121086066A (zh) * 2024-12-19 2025-12-09 合肥工业大学 牛乳铁蛋白多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141581A (en) * 1972-10-08 1992-08-25 Markham Harold A Implants with a cover which resists formation of firm spherical encapsulation
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5073542A (en) 1989-06-07 1991-12-17 Magainin Sciences Inc. CPF peptide compositions and their use in inhibiting growth of target cells or a virus
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
JP2818056B2 (ja) * 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
DE69220397T2 (de) * 1991-03-13 1997-10-02 Morinaga Milk Industry Co Ltd Antimikrobielles Peptid und antimikrobieller Wirkstoff
JPH06511234A (ja) * 1991-06-12 1994-12-15 マゲイニン　ファーマス−ティカルズ，インコーポレーテッド Ｃ末端置換を有する生物活性ペプチド組成物および治療法
US5547939A (en) * 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5646119A (en) * 1991-11-01 1997-07-08 Periodontix, Inc. D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents
US5631228A (en) * 1991-11-01 1997-05-20 Periodontix, Inc. Anti-fungal and anti-bacterial histatin-based peptides
AU665381B2 (en) 1992-01-23 1996-01-04 Morinaga Milk Industry Company Limited Antibacterial agent and treatment of article therewith
CA2137087A1 (en) * 1992-06-01 1993-12-09 U. Prasad Kari Biologically active peptides having n-terminal substitutions
DE69332377T2 (de) * 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
CA2150946A1 (en) 1992-12-03 1994-06-09 Leonard S. Jacob Treatment of dermatological malignancies with biologically active peptides
JP3312946B2 (ja) * 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
JP2001504447A (ja) * 1996-08-12 2001-04-03 エイプラス サイエンス インベスト アーベー ラクトフェリンおよび／またはラクトフェリシンでの、感染、炎症および／または腫瘍の処置および予防
WO1998006860A1 (en) * 1996-08-14 1998-02-19 Novartis Ag Peptide with inhibitory activity towards plant pathogenic fungi
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
WO1998040091A1 (en) * 1997-03-13 1998-09-17 The Research Foundation Of State University Of New York Microbicidal peptides and methods of use
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides

Also Published As

Publication number Publication date
NO20010995L (no) 2001-04-27
EP1109831B1 (de) 2011-01-12
US8143211B2 (en) 2012-03-27
DK1109831T3 (da) 2011-04-18
NO333073B1 (no) 2013-02-25
AU772176B2 (en) 2004-04-08
US20030022821A1 (en) 2003-01-30
US7439228B2 (en) 2008-10-21
EP1109827A2 (de) 2001-06-27
EP1109827B1 (de) 2011-06-22
WO2000012541A3 (en) 2000-06-08
ES2359616T3 (es) 2011-05-25
WO2000012542A3 (en) 2000-06-29
US20030148936A1 (en) 2003-08-07
DE69943130D1 (de) 2011-02-24
CA2341037A1 (en) 2000-03-09
AU5526799A (en) 2000-03-21
GB9818938D0 (en) 1998-10-21
WO2000012542A2 (en) 2000-03-09
US6890902B2 (en) 2005-05-10
JP5475937B2 (ja) 2014-04-16
WO2000012541A2 (en) 2000-03-09
ATE513847T1 (de) 2011-07-15
JP2002523517A (ja) 2002-07-30
NO20010995D0 (no) 2001-02-27
EP1109831A2 (de) 2001-06-27
CA2340326A1 (en) 2000-03-09
US20080287346A1 (en) 2008-11-20
CA2341037C (en) 2013-11-05
AU5526899A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
DE69943130D1 (de) Mit voluminösen oder lipophilen gruppen modifizierte cyctotoxische peptide
DK0528312T3 (da) Cykliske peptider og anvendelse deraf
PL344599A1 (en) Novel cyclosporins
EP0696208A4 (de) Orale dareichungsform und verfahren
BR9807076B1 (pt) "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
IL127352A (en) Pyridyl alkene- and pyridyl alkine-acid amides and pharmaceutical compositions containing them
FI905956A0 (fi) Foerfarande foer producering av ett biologiskt aktivt protein.
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
ATE165100T1 (de) Peptide mit endothelin antagonistischer aktivität, deren herstellung und pharmazeutische zusammensetzungen
DE69709407D1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
FR2647677B1 (fr) Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DE60117247D1 (de) Phosphoramidat-prodrugs
ES2133295T3 (es) Peptidos ciclicos y su uso.
MX9302327A (es) Aminoacidos ciclicos novedosos y derivados de los mismos.
MXPA01011955A (es) Aminoacidos policiclicos, fusionados, como agentes farmaceuticos.
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
IL139400A0 (en) Long-acting cytokine derivatives and pharmaceutical compositions comprising them
DE69412612D1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
FR2766489B1 (fr) Derives de streptogramines, leur preparation et les compositions qui les contiennent
AR018328A1 (es) Forma cristalina de la 1s-[1 alfa(2s*,3r*), 9 alfa-]-6,10-dioxo-n-(2-etoxi-5-oxo-tetrahidro-3-furanil)-9-[[(1-isoquinolil)carbonil]amino]octahidro-6-h-piridazino[1,2-a][1,2] diazepina-1-carboxamida, su procedimiento de preparacion , su aplicacion en la preparacion de un medicamento, y las composicio
DE69808287D1 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1109831

Country of ref document: EP